$CYTR is now a strong buy with average target pric
Post# of 22757
Posted On: 06/17/2015 9:54:47 AM
$CYTR is now a strong buy with average target price of $9.33, you can get shares under $4 now. This is an amazing stock and should be in everyone's portfolio. This is a gem in biotech.
http://www.americantradejournal.com/zacks-rat...on/612784/
CytRx Corporation (NASDAQ:CYTR) remains a strong buy in the latest set of rankings. The counter has received an average rating of 1 by 3 analysts. Zacks has advised to Sell for the short term with a rating of 4. CytRx Corporation (NASDAQ:CYTR): 3 Analyst have given the stock of CytRx Corporation (NASDAQ:CYTR) a near short term price target of $9.33 . The standard deviation reading, which is a measure by which the stock price is expected to swing away from the mean estimate, is at $1.15. The higher price target estimate is at $10 while the lower price estimates are fixed at $8.
The company has received recommendation from many analysts. 2 analysts have rated the company as a strong buy. 2 analysts have suggested buy for the company.
CytRx Corporation (NASDAQ:CYTR) rose 2.37% or 0.09 points on Tuesday and made its way into the gainers of the day. After trading began at $3.77 the stock was seen hitting $3.9 as a peak level and $3.77 as the lowest level. The stock ended up at $3.88. The daily volume was measured at 385,948 shares. The 52-week high of the share price is $5.42 and the 52-week low is $2.08. The company has a market cap of $216 million.
Several Brokerage firms have commented on company shares. FBR Capital initiates coverage on CytRx Corporation (NASDAQ:CYTR). The shares have now been rated Outperform by the stock experts at the ratings house. FBR Capital announces the current price target of $8 per share on CytRx Corporation.
CytRx Corporation (CytRx) is a biopharmaceutical research and development company specializing in oncology. The Companys oncology pipeline includes three programs in clinical development for cancer indications: INNO-206, tamibarotene and bafetinib. INNO-206 is the Companys tumor-targeted doxorubicin conjugate. On May 13, 2011, the Company sold all pre-clinical and clinical data, intellectual property rights and other assets relating to those compounds to Orphazyme ApS. During the year ended December 31, 2011, the Company sold of its 19% interest in SynthRx to ADVENTRX Pharmaceuticals.
http://www.americantradejournal.com/zacks-rat...on/612784/
CytRx Corporation (NASDAQ:CYTR) remains a strong buy in the latest set of rankings. The counter has received an average rating of 1 by 3 analysts. Zacks has advised to Sell for the short term with a rating of 4. CytRx Corporation (NASDAQ:CYTR): 3 Analyst have given the stock of CytRx Corporation (NASDAQ:CYTR) a near short term price target of $9.33 . The standard deviation reading, which is a measure by which the stock price is expected to swing away from the mean estimate, is at $1.15. The higher price target estimate is at $10 while the lower price estimates are fixed at $8.
The company has received recommendation from many analysts. 2 analysts have rated the company as a strong buy. 2 analysts have suggested buy for the company.
CytRx Corporation (NASDAQ:CYTR) rose 2.37% or 0.09 points on Tuesday and made its way into the gainers of the day. After trading began at $3.77 the stock was seen hitting $3.9 as a peak level and $3.77 as the lowest level. The stock ended up at $3.88. The daily volume was measured at 385,948 shares. The 52-week high of the share price is $5.42 and the 52-week low is $2.08. The company has a market cap of $216 million.
Several Brokerage firms have commented on company shares. FBR Capital initiates coverage on CytRx Corporation (NASDAQ:CYTR). The shares have now been rated Outperform by the stock experts at the ratings house. FBR Capital announces the current price target of $8 per share on CytRx Corporation.
CytRx Corporation (CytRx) is a biopharmaceutical research and development company specializing in oncology. The Companys oncology pipeline includes three programs in clinical development for cancer indications: INNO-206, tamibarotene and bafetinib. INNO-206 is the Companys tumor-targeted doxorubicin conjugate. On May 13, 2011, the Company sold all pre-clinical and clinical data, intellectual property rights and other assets relating to those compounds to Orphazyme ApS. During the year ended December 31, 2011, the Company sold of its 19% interest in SynthRx to ADVENTRX Pharmaceuticals.
(0)
(0)Scroll down for more posts ▼